Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
468
datasets available to search
ShareScore release 0.9.0
Dataset results
468 results for “HLA”
Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies
ClinicalTrials.gov study NCT03270748. IPD Sharing: Not stated. Countries: 1. Publications: 1.
HLA class I and class II allelic profile of healthy Lebanese population
Open the record for dataset details and reuse information.
Data from: HLA-G 14 bp variant is associated with exercise-induced oxygen desaturation in the post-COVID-19 condition
Open the record for dataset details and reuse information.
Data from: A large fraction of HLA class I ligands are proteasome-generated spliced peptides
The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules that elicit CD8+ T cell responses. Reports of proteasome-generated spliced epitopes exist, but they have been regarded as rare events. Here, however, we show that the proteasome-generated spliced peptide pool accounts for one-third of the entire HLA class I immunopeptidome in terms of diversity and one-fourth in terms of abundance. This pool also represents a unique set of antigens, possessing particular and distinguishing features. We validated this observation using a range of complementary experimental and bioinformatics approaches, as well as multiple cell types. The widespread appearance and abundance of proteasome-catalyzed peptide splicing events has implications for immunobiology and autoimmunity theories and may provide a previously untapped source of epitopes for use in vaccines and cancer immunotherapy.
Supplementary data --The mutational landscape of SARS-CoV-2 variants diversifies T cell targets in an HLA supertype-dependent manner
<p>Supplementary data for the Cell Systems manuscript 'The mutational landscape of SARS-CoV-2 variants diversifies T cell targets in an HLA supertype-dependent manner', by Hamelin <em>et al.</em></p> <p><strong>GISAID_Authors_Recognition_2021-01-19. </strong>Metadata concerning the SARS-CoV-2 viral sequences analysed, and generously provided by GISAID. </p> <p><strong>Table S1. </strong>SARS-CoV-2 mutations identified from 330,246 GISAID entries (December 31<sup>st</sup> 2020), Related to Figure 1 and Figure 2. SARS-CoV-2 mutations at the nucleic and amino acid level are indicated. Number of genomes carrying mutation show the frequency of individual mutations among all SARS-CoV-2 variants. </p> <p><strong>Table S2. </strong>SARS-CoV-2 prevalent mutations identified from 330,246 GISAID entries (December 31<sup>st</sup> 2020) and detected in at least 100 individuals, Related to Figure 2.</p> <p><strong>Table S3.</strong> Previously validated SARS-CoV-2 CD8+ T cell epitopes and their matching mutated forms identified in this study, Related to Figure 1 and Figure 2.</p> <p><strong>Table S4.</strong> List of previously validated SARS-CoV-2 CD8+ T cell epitopes. Epitopes were downloaded from https://www.mckayspcb.com/SARS2TcellEpitopes/ (as of January 2021). This database has effectively catalogued all SARS-CoV-2 CD8+ epitopes validated by 18 separate studies. See Quadeer et al. 2021 for details, Related to Figure 1 and Figure 2. </p>
Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Pat
ClinicalTrials.gov study NCT00629798. IPD Sharing: Not stated. Countries: 1. Publications: 0.
GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Tra
ClinicalTrials.gov study NCT02360111. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
ClinicalTrials.gov study NCT04093323. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation
ClinicalTrials.gov study NCT01349595. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
ClinicalTrials.gov study NCT03615105. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)
ClinicalTrials.gov study NCT04752358. IPD Sharing: Not stated. Countries: 3. Publications: 0.
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
ClinicalTrials.gov study NCT00714259. IPD Sharing: NO. Countries: 1. Publications: 0.
Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study
ClinicalTrials.gov study NCT07038070. IPD Sharing: YES. Countries: 1. Publications: 0.
Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation
ClinicalTrials.gov study NCT01749293. IPD Sharing: Not stated. Countries: 1. Publications: 0.
SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD
ClinicalTrials.gov study NCT02013375. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Pat
ClinicalTrials.gov study NCT00587054. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma
ClinicalTrials.gov study NCT00003895. IPD Sharing: Not stated. Countries: 1. Publications: 0.
PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
ClinicalTrials.gov study NCT00694551. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor
ClinicalTrials.gov study NCT01598025. IPD Sharing: Not stated. Countries: 1. Publications: 0.
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML
ClinicalTrials.gov study NCT04620681. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.